These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25808060)

  • 1. Relationship between vitamin D status and response to hepatitis C virus therapy.
    Kitson MT; Sarrazin C; Toniutto P; Roberts SK
    Hepatology; 2015 Nov; 62(5):1642-3. PubMed ID: 25808060
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: To PMID 24975775.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Fernández-Rodríguez A; Resino S
    Hepatology; 2015 Nov; 62(5):1643. PubMed ID: 25807876
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis.
    García-Álvarez M; Pineda-Tenor D; Jiménez-Sousa MA; Fernández-Rodríguez A; Guzmán-Fulgencio M; Resino S
    Hepatology; 2014 Nov; 60(5):1541-50. PubMed ID: 24975775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection.
    Cholongitas E; Theocharidou E; Goulis J; Tsochatzis E; Akriviadis E; Burroughs K
    Aliment Pharmacol Ther; 2012 Mar; 35(6):634-46. PubMed ID: 22316435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D controls T cell activation: implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C.
    Shen L
    Hepatology; 2010 Nov; 52(5):1864. PubMed ID: 20672383
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C. An update.
    Bren L
    FDA Consum; 2001; 35(4):24-9. PubMed ID: 11692881
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating Hepatitis C.
    Grennan D
    JAMA; 2018 Dec; 320(21):2280. PubMed ID: 30512101
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?
    Karlas T; Benckert J; Beer S; Keim V; Berg T; Wiegand J
    Aliment Pharmacol Ther; 2016 Feb; 43(4):543-4. PubMed ID: 26753820
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of pretransplant and posttransplant viral cirrhosis].
    Suárez FJ; Otero A; Gómez M; Souto J; Vázquez-Iglesias JL
    Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():58-63. PubMed ID: 11279895
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: can persisting liver stiffness indicate increased risk for HCC, after successful anti-HCV therapy? - authors' reply.
    Mandorfer M; Kozbial K; Peck-Radosavljevic M; Ferenci P
    Aliment Pharmacol Ther; 2016 Feb; 43(4):544-5. PubMed ID: 26753821
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 14. [Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
    Sugawara Y; Makuuchi M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):605-9. PubMed ID: 15359869
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply.
    Deterding K; Schlevogt B; Port K; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2016 Feb; 43(4):546-7. PubMed ID: 26753822
    [No Abstract]   [Full Text] [Related]  

  • 16. EVALUATION OF ANTIVIRAL THERAPY TREATMENT FOR LIVER CIRRHOSIS CAUSED BY CHRONIC HEPATITIS C AND HEPATITIS C BY 31P-MRS, BASED ON METABOLITE DETECTION.
    Gu JS; Sun RR; Shen S; Yu ZJ
    J Biol Regul Homeost Agents; 2015; 29(2):443-50. PubMed ID: 26122235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010.
    Brook G; Main J; Nelson M; Bhagani S; Wilkins E; Leen C; Fisher M; Gilleece Y; Gilson R; Freedman A; Kulasegaram R; Agarwal K; Sabin C; Deacon-Adams C;
    HIV Med; 2010 Jan; 11(1):1-30. PubMed ID: 20059574
    [No Abstract]   [Full Text] [Related]  

  • 18. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C: practical aspects.
    Schalm SW; Brouwer JT
    Acta Gastroenterol Belg; 1997; 60(3):204-10. PubMed ID: 9396176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.